Title : ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Pub. Date : 2018 Jun 1

PMID : 29581135






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Purpose: This study aimed to identify biomarkers of resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancers treated with prolonged neoadjuvant letrozole.Experimental Design: We performed targeted DNA and RNA sequencing in 68 ER+ breast cancers from patients treated with preoperative letrozole (median, 7 months).Results: Twenty-four tumors (35%) exhibited a PEPI score >=4 and/or recurred after a median of 58 months and were considered endocrine resistant. Letrozole estrogen receptor 1 Homo sapiens